- 期刊
- OpenAccess
Use of Tumor Necrosis Factor-α Antagonists in Patients with Concurrent Rheumatoid Arthritis or Spondyloarthritis and Hepatitis B
抗腫瘤壞死因子藥物在慢性肝炎合併風濕病患者之使用
摘要
目的：研究生物製劑治療風濕病在B型肝炎病人的安全性。方法：回溯性地研究自西元2002年1月至2010年9月間使用恩博或復邁的風濕病人，分析病人肝功能及病毒量判斷是否有B型肝炎再活動。結果：161個使用恩博或復邁的風濕病人中，有17人B肝表面抗原陽性且皆未使用預防性抗病毒治療，排除其中9人無治療前病毒量以致無法判斷治療後是否有B型肝炎再活動，我們分析其餘8個病人之中只有1人（12.5%）在治療後4個月疑有B型肝炎再活動，在沒有使用抗病毒藥且繼續使用生物製劑的情況下，病人的肝功能自行回到正常值。結論：所有病人在使用生物製劑之前都需檢測B型肝炎，並於療程期間定期追蹤肝功能，若有B型肝炎再活動證據，應使用抗病毒藥治療，然而預防性的抗病毒治療未必是需要的。
並列摘要
Objective: To assess the safety of biological agents in patients with rheumatic diseases associated with hepatitis B in one medical center.Methods: Patients who had taken etanercept or adalimumab from January 2002 to September 2010 in Chung Shan Medical University Hospital were reviewed in the study. We retrospectively investigated a series of serum aminotransferase (ALT) levels, hepatitis serologic status including HBV surface antigen (HBsAg), HBV surface antibody (HBsAb), HBV core IgG Ab (HBcAb), and HBV-DNA. Endpoints were clinical reactivation and subclinical reactivation as defined by ALT and viral load, respectively.Results: A total of 161 patients were documented to have taken etanercept or adalimumab. Among the 161 patients, 17 (10.56%) patients had chronic hepatitis B (HbsAg+) without anti-viral agent prophylaxis prior to biologics. Nine patients were excluded from the analysis due to missing data. Of these remaining 8 patients, only 1 (12.5%) patient had transient mild clinical reactivation after taking etanercept for 4 months. Spontaneous remission of this patient’s HBV reactivation was noted without anti-viral therapy.Conclusion: All rheumatic patients who plan to take biologics treatment should undergo tests for HBV, and they should have a close follow-up with ALT during therapy. Preemptive anti-viral therapy is commenced in patients who develop evidence of disease reactivation. For chronic hepatitis patients, it might not be necessary to use a prophylactic anti-viral agent prior to biologics.
延伸閱讀
- Leong, P. Y., Chen, C. Y., Huang, C. H., Chen, Y. L., Yeo, K. J., Cherng, J. M., Wang, S. R., Tsay, G. J., Chen, P. J., & Wei, J. C. C. (2012). 研究使用抗腫瘤壞死因子治僵直性脊椎炎或類風濕關節炎合併慢性B型肝炎的病人的肝癌預估風險. Formosan Journal of Rheumatology, 26(1&2), 116-124. https://doi.org/10.6313/FJR.2012.26(1-2).16
- 翁國益、許秉寧（2009）。《免疫網絡》類風濕性關節炎治療的新里程碑淺談腫瘤壞死因子抑制劑。健康世界，(286)，61-63。https://doi.org/10.6454/HW.200910.0061
- Huang, C. M., Chen, C. L., Lin, T. H., & Wang, H. J. (1999). 類風濕性關節炎和退化性關節炎病患之血清和關節液腫瘤壞死因子及接受體之偵測. Mid-Taiwan Journal of Medicine, 4(2), 109-115. https://doi.org/10.6558/MTJM.1999.4(2).6
- 王嘉珍、蘇建豪、戴慶玲、賴漢明、陳英州（2020）。類風濕性關節炎病人接受免疫抑制治療對B型肝炎病毒再活化之影響。臺灣臨床藥學雜誌，28(3)，219-230。https://doi.org/10.6168/FJCP.202007_28(3).0007
- Chen, C. Y., Chen, H. A., Chen, M. H., Lin, Y. J., Lin, C. Y., Chen, C. S., Liao, H. T., Chou, C. T., Weng, S. F., Chu, C. C., Liu, C. H., Wang, J. J., & Chen, C. H. (2016). 類風濕性關節炎病人新發生心臟事件的危險因子：methotrexate和腫瘤壞死因子拮抗劑的心臟保護效果. Formosan Journal of Rheumatology, 30(1), 33-42. https://doi.org/10.6313/FJR.2016.30(01).04